Cowen & Co
http://www.cowen.com/default.htmlCowen and Company offers investment banking services, including equity research, equity and convertible debt financings, mergers and acquisitions advisory services, and restricted security sales.
View Older Stories
-
Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
-
Trillium Therapeutics (TRIL) Announces Pricing of $101.7M Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
-
Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
-
Trillium Therapeutics (TRIL) Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
-
Trillium Announces Proposed Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
-
Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
-
Trillium Therapeutics (TRIL) Pricing of $15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
-
Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
-
Trillium Therapeutics (TRIL) to Offer Common Units and Convertible Units
-
Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
-
Trillium Therapeutics Announces “At-The-Market” Issuance Program and Filing of Prospectus Supplement
-
Trillium Therapeutics to Present at Investor and Scientific Conferences in the First Quarter
-
Trillium Announces Closing of Private Placement
-
Trillium Therapeutics (TRIL) Reports $19.98M Private Placement
-
Trillium Announces Private Placement
-
Trillium Announces Partial Exercise of Over-Allotment Option
-
Trillium Closes US$30 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
-
Pre-Open Movers 05/26: (NTNX) (DECK) (WEB) Higher; (ZOES) (NAKD) (GME) Lower (more...)
-
Trillium Therapeutics (TRIL) Prices 2.75M Shares at $5, Prices 3.25M Convertible Preferred Shares
-
Trillium Announces Pricing of US$30.0 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preference Shares
-
Trillium Therapeutics (TRIL) Plans Offering of Common Stock and Series II Non-Voting Convertible First Preferred Shares
-
Trillium Announces Proposed Public Offering
-
Notable Analyst Rating Changes 8/3: (ZNGA) (NMBL) (AVD) Upgraded; (CSIQ) (EQR) (EMR) Downgraded
-
Trillium to Present at the Cowen and Company 36th Annual Health Care Conference
-
UPDATE: Cowen Starts Trillium Therapeutics (TRIL) at Outperform
-
Trillium Therapeutics Announces Completion of Public Offering of Securities
-
Trillium Therapeutics Announces Completion of Public Offering of Securities
-
UPDATE: Trillium Therapeutics (TRIL) Prices 1.52M Common Offering at $19.50/Share
-
Trillium Therapeutics Announces Pricing of Public Offering of Securities
-
Trillium Therapeutics (TRIL) Announces $50M Common Stock Offering
-
Trillium Therapeutics Announces Proposed Public Offering of Securities
-
Trillium Therapeutics Announces Proposed Public Offering of Securities